TY - JOUR
T1 - Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors
AU - Zhu, Mojun
AU - Bassam Sonbol, Mohamad
AU - Halfdanarson, Thorvardur
AU - Hobday, Timothy
AU - Ahn, Daniel
AU - Ma, Wen Wee
AU - Bekaii-Saab, Tanios
N1 - Publisher Copyright:
© AlphaMed Press 2020
PY - 2020/8/1
Y1 - 2020/8/1
N2 - Lutetium-177-dotatate (177Lu-dotatate), a form of peptide receptor radionuclide therapy, was approved by the U.S. Food and Drug Administration for the treatment of advanced somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors (NETs) in 2018 based on the promising results of the NETTER-1 trial for grade 1–2 midgut NETs. Here, we present a patient with a grade 3 pancreatic neuroendocrine tumor and BRCA1 germline mutation who had a significant response to 177Lu-dotatate.
AB - Lutetium-177-dotatate (177Lu-dotatate), a form of peptide receptor radionuclide therapy, was approved by the U.S. Food and Drug Administration for the treatment of advanced somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors (NETs) in 2018 based on the promising results of the NETTER-1 trial for grade 1–2 midgut NETs. Here, we present a patient with a grade 3 pancreatic neuroendocrine tumor and BRCA1 germline mutation who had a significant response to 177Lu-dotatate.
UR - http://www.scopus.com/inward/record.url?scp=85087165373&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087165373&partnerID=8YFLogxK
U2 - 10.1634/theoncologist.2020-0029
DO - 10.1634/theoncologist.2020-0029
M3 - Article
C2 - 32510802
AN - SCOPUS:85087165373
SN - 1083-7159
VL - 25
SP - e1246-e1248
JO - Oncologist
JF - Oncologist
IS - 8
ER -